The Q2 earning season is drawing to a close as we now have releases from approximately 433 S&P 500 members, accounting for 87.7% of the index’s total market capitalization. Even though earnings put up a 4.1% decline on 0.9% lower revenues, almost 70.7% of the companies have managed to beat on earnings, while 52.7% surpassed top-line expectations. This week, investors will be looking forward to quarterly numbers of approximately 67 companies.

These positive trends notwithstanding, Q2 is still on track to be the fifth quarter in a row to record negative earnings growth. Overall, earnings for the benchmark index are expected to decline 3.5% on 0.4% lower revenues. Moreover, estimates for the third quarter are still moving south. Nevertheless, positive earnings growth is anticipated in the fourth quarter, which will be followed by double-digit earnings growth for the S&P 500 index.

Medical was one of the few sectors that were expected to record positive earnings growth this quarter, braving a challenging business environment fraught with headwinds like unfavorable currency movements and biosimilars. In the medical sector, 86.5% S&P 500 members have reported results so far. Average earnings in the sector recorded 6.5% growth on 9.9% higher revenues, resulting in a blended beat of 77.8%. It is evident that the sector’s results have surpassed expectations so far, which will allow wary investors heave a sigh of relief.

A few companies in the Medical sector are slated to report earnings on Aug 10. Lets see what is in store for them.

First up, Spark Therapeutics , a fully integrated gene therapy company, is scheduled to report second quarter results on Aug 10. The company is working on addressing serious genetic diseases, including inherited retinal diseases, liver-associated diseases, such as hemophilia, and neurodegenerative diseases. The company has a dismal track record having missed earnings three times in the last four quarters with an average negative surprise of 92.31%. Moreover, the company’s current Zacks Rank #3 and an Earnings ESP of 0.0% make surprise prediction difficult this quarter.

Collegium Pharmaceutical, Inc. (COLL Quick QuoteCOLL - Free Report) is scheduled to report second-quarter results on Aug 10. This specialty pharmaceutical company focused on developing a portfolio of products using its proprietary DETERx technology platform for the treatment of chronic pain and other diseases. Collegium’s first product, Xtampza ER, is approved by the FDA for the management of severe pain. The company has a dismal track record having missed earnings in three times in the last four quarters with an average negative surprise of 33.9%. Moreover, the company’s current Zacks Rank #3 and an Earnings ESP of 0.0% make surprise prediction difficult this quarter.

Argos Therapeutics Inc. is scheduled to report second-quarter results on Aug 10. This immuno-oncology company primarily focuses on the development and commercialization of immunotherapies based on its technology platform Arcelis. The company’s lead product candidate, AGS-003, is being evaluated for the treatment of metastatic renal cell carcinoma. Argos’ track record is dismal too having missed earnings thrice in the last four quarters with an average negative surprise of 6.5%. The company’s current Zacks Rank #3 is favorable but its ESP of 0.0% makes surprise prediction difficult this quarter.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>